NKGN vs. SRZN, INKT, TARA, INAB, CRTX, ESLA, ACHL, SABS, PLUR, and DYAI
Should you be buying NKGen Biotech stock or one of its competitors? The main competitors of NKGen Biotech include Surrozen (SRZN), MiNK Therapeutics (INKT), Protara Therapeutics (TARA), IN8bio (INAB), Cortexyme (CRTX), Estrella Immunopharma (ESLA), Achilles Therapeutics (ACHL), SAB Biotherapeutics (SABS), Pluri (PLUR), and Dyadic International (DYAI). These companies are all part of the "medical" sector.
NKGen Biotech (NYSE:NKGN) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.
NKGen Biotech has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Surrozen has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500.
In the previous week, Surrozen had 4 more articles in the media than NKGen Biotech. MarketBeat recorded 4 mentions for Surrozen and 0 mentions for NKGen Biotech. NKGen Biotech's average media sentiment score of 0.67 beat Surrozen's score of 0.00 indicating that NKGen Biotech is being referred to more favorably in the media.
Surrozen received 3 more outperform votes than NKGen Biotech when rated by MarketBeat users.
76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 20.0% of NKGen Biotech shares are held by company insiders. Comparatively, 43.5% of Surrozen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Surrozen has higher revenue and earnings than NKGen Biotech.
NKGen Biotech's return on equity of 0.00% beat Surrozen's return on equity.
Summary
Surrozen beats NKGen Biotech on 7 of the 11 factors compared between the two stocks.
Get NKGen Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NKGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NKGen Biotech Competitors List
Related Companies and Tools
